#news #biotech Midphase failure of Novartis’ NASH drug crushes Conatus

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Midphase failure of Novartis’ NASH drug crushes Conatus .A phase 2b trial of Conatus Pharmaceuticals’ emricasan has missed its primary endpoint. The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.

from FierceBiotech: Biotech https://ift.tt/2L21XJp